BioSpace News Archive

Agilent Technologies Inc. (NYSE: A) today announced the latest implementation of its mutual compatibility philosophy

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that, following approval by its shareholders and satisfaction of other closing conditions, the global strategic oncology collaboration with Amgen

Amgen (NASDAQ: AMGN) today announced the successful closing of the transaction to enter into a strategic collaboration with BeiGene that will significantly accelerate Amgen’s plans to expand its oncology presence in China, the world’s second-largest pharmaceutical market.

Pulpdent Corporation, a Boston-area dental research and manufacturing company, has launched ACTIVA Presto, a new white dental filling material that mimics the properties of natural teeth.

Align Technology, Inc. (Nasdaq: ALGN) announced today that the Company will report fourth quarter and 2019 financial results on Wednesday, January 29, 2020, after the close of market.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that, effective December 31, 2019, Debra Donaghy, CPA, CMA, CTP, has been appointed to its Board of Directors as an independent director and will also serve as a member of the Company’s Audit Committee.

The data highlights INmune Bio’s lead compound, XPro1595, as a potentially effective therapy to lower the risk for Alzheimer’s disease in obese individuals.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 38th Annual J.P. Morgan Healthcare Conferenc

Abbott will announce its fourth-quarter 2019 financial results on Wednesday, Jan. 22, 2020, before the market opens.

DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis.